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A B S T R A C T
Background: Stent thrombosis (ST) has emerged as a severe complication of percutaneous coronary
intervention (PCI). Since the occurrence of ST is lower in Japan than Western countries, there are few data
to predict ST after drug-eluting stent (DES) implantation in Japan. We examined the independent
predictors of ST incidence after DES implantation in Japanese patients, including the use of calcium
channel blockers (CCBs).
Methods and results: We used data from the Kumamoto Intervention Conference Study registry. There
were 6286 consecutive patients enrolled from June 2008 to March 2011. Among them, we analyzed
3493 patients who underwent DES implantation. The incidence of deﬁnite/probable ST throughout a
median follow-up period of 364 days was 0.57% (20 patients). There were 8 patients with early ST (within
30 days), 8 patients with late ST (between 31 and 365 days), and 4 patients with very late ST (after
1 year). The frequency of CCB use was signiﬁcantly lower in ST than non-ST patients (25.0% versus 51.4%,
respectively, p = 0.016). Multiple regression analysis showed that longer stent length (p = 0.034), acute
coronary syndrome (p = 0.039), and the absence of CCB use (p = 0.046) were signiﬁcant and independent
predictors of ST within 1 year.
Conclusions: These results suggest that CCB use may be associated with a decreased risk of ST after DES
implantation within 1 year in Japanese patients.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Percutaneous coronary intervention (PCI) is an established
treatment for coronary heart disease (CHD) [1]. Stent thrombosis
(ST) has emerged as a severe complication of PCI with stenting
[2]. Regardless of the drug-eluting stent (DES) or bare metal stent
(BMS), concern about ST has been raised including the timing, such
as early, late, and very late phases, especially in acute coronary* Corresponding author at: Department of Cardiovascular Medicine, Graduate
School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku,
Kumamoto City 860-8556, Japan. Tel.: +81 96 373 5175; fax: +81 96 362 3256.
E-mail address: shokimot@kumamoto-u.ac.jp (S. Hokimoto).
1 Members of KICS are listed in Appendix A.
http://dx.doi.org/10.1016/j.jjcc.2014.11.013
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightssyndrome (ACS) patients [3,4]. Although DES implantation is
reported to be associated with very late stent thrombosis [5,6],
recent studies demonstrate that there is no concern about stent
thrombosis regarding second generation DESs [7]. The occurrence of
ST is lower in Japan than Western countries [3,4]; therefore, there are
few data to predict ST after DES implantation in Japanese patients.
Dual antiplatelet therapy (DAPT) is currently recommended for the
prevention of adverse cardiovascular events in patients undergoing
PCI and patients with ACS [8–10]. However, ST also may occur in
patients who are taking DAPT. It remains unknown whether any
other drug therapy affects the occurrence of ST after DES
implantation. The present study was therefore conducted to
examine the independent predictors of ST after DES implantation
in Japanese patients, including prescription drug therapy. reserved.
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Study population
We used data from the Kumamoto Intervention Conference
Study (KICS) registry. KICS is a physician-initiated, non-company-
sponsored, multicenter registry enrolling consecutive procedures
undergoing PCI in 16 centers in Japan. Written informed consent
was obtained from all patients. There were 6286 consecutive
patients who underwent PCI between June 2008 and March
2011. The exclusion criteria were: (1) percutaneous balloon
angioplasty or thrombus aspiration without coronary stent
implantation, (2) unsuccessful PCI, and (3) in-hospital death.
We excluded in-hospital death because we would like to examine
the effect of any prescriptions for ST. We excluded 2 in-hospital
deaths by ST because both cases occurred before stable conditions.
The selection of treatment was left to the discretion of the
attending physicians at each hospital. After excluding 557 patients
based on the criteria above, there were 5729 patients who
underwent stent implantation. Among these patients, 3493 had
successful DES implantation and were used in the ﬁnal analysis
(Fig. 1).
Clinical outcomes and deﬁnitions
The endpoint of this study was the occurrence of deﬁnite/
probable ST. ST was deﬁned according to the Academic Research
Consortium criteria [11]. Cardiovascular (CV) events were deﬁned
as CV death, non-fatal myocardial infarction (MI), and ischemic
stroke. CV death was deﬁned as death from MI, congestive heart
failure or documented sudden cardiac death. The universal
deﬁnition of MI was used [12]. We performed a follow-up survey
to evaluate clinical outcomes throughout a median follow-up
period of median 364 days (261–523 days).
Statistical analysis
Continuous variables are expressed as the mean  SD. Cate-
gorical variables are expressed as frequencies and percentages.
Continuous variables were compared between groups using a
Student’s t-test, and categorical variables were compared using a
chi-square test. Univariate and multivariate logistic regression
analyses were performed to determine the predictors of ST. The oddsFig. 1. Study population. There were 6286 consecutive patients who underwent PCI betw
above, there were 5729 patients who underwent stent implantation. Among these patie
percutaneous coronary intervention; DES, drug-eluting stent; BMS, bare metal stent.ratios (ORs) and 95% conﬁdence intervals (CIs) were determined
from the logistic regression analysis. A p-value <0.05 was regarded




In 3493 patients who underwent DES implantation, the
incidence of deﬁnite/probable ST throughout a median follow-
up period of 364 days was 0.57% (20 patients). There were 18
(90%) deﬁnite and 2 (10%) probable ST. There were 8 patients with
early ST (EST, within 30 days), 8 patients with late ST (LST, from
31 to 365 days), and 4 patients with very late ST (VLST, after
1 year). The longest duration until ST occurrence was 810 days
after PCI. Table 1A shows the clinical characteristics according to
ST incidence. The rate of ACS was signiﬁcantly higher in the ST
than the non-ST group (65.0% versus 36.3%, respectively,
p = 0.009). When we replaced ACS with unstable angina pectoris
or acute MI, the results were similar. Other parameters, such as
general health status and classical risk factors, were similar
between the two groups. Table 1B shows the angiographic
characteristics of each group. The presence of emergency PCI,
severe pre-stenosis, and acute occlusion (as a complication) was
signiﬁcantly higher in the ST than non-ST group. In the ST group,
the mean stent diameter was signiﬁcantly smaller (2.5  0.7 mm
versus 2.9  0.8 mm, p = 0.033) and stent length was signiﬁcantly
longer (23.8  4.5 mm versus 20.6  6.7 mm, p = 0.001) than in the
non-ST group. Lesion complexity, the use of mechanical supports,
and the complication rate were similar between the two groups.
Fig. 2 shows the occurrence of ST based on the actual number of DESs
implanted (5371) rather than the number of patients (3493).
Sirolimus-eluting (SES) (26.4%), paclitaxel-eluting (PES) (27.6%),
and everolimus-eluting (EES) (25.8%) stents were the major stent
types used in this study. The occurrence of ST was 0.49% in SES,
0.40% in PES, 0.35% in zotarolimus-eluting stent (ZES), and 0.25% in
EES. EES showed lower rate of ST occurrence compared with any
other stents, especially ﬁrst-generation DES (SES and PES). These
results corresponded with a previous study [7]. The occurrence of ST
after 1 year (VLST) was lower in second-generation DES (ZES and
EES) (14.3%) compared with ﬁrst-generation DES (SES and PES)
(23.1%).een June 2008 and March 2011. After excluding 557 patients based on the criteria
nts, 3493 had successful DES implantation and were used in the ﬁnal analysis. PCI,
Table 1A
Comparison of clinical characteristics between non-stent thrombosis and stent thrombosis.
All (n = 3493) Non-ST (n = 3473) ST (n = 20) p
Male 2492 (71.3%) 2478 (71.4%) 14 (70.0%) 0.529
Age (years) 69.8  10.2 69.8  10.2 68.0  9.9 0.425
BMI (kg/m2) 24.0  3.6 24.0  3.6 23.0  3.2 0.210
HbA1c (%) 6.2  1.3 6.2  1.3 6.6  1.1 0.266
Prior MI 860 (24.6%) 855 (24.6%) 5 (25.0%) 0.570
Prior CABG 218 (6.2%) 215 (6.2%) 3 (15.0%) 0.125
Prior stroke 491 (14.1%) 486 (14.0%) 5 (25.0%) 0.139
Prior PAD 327 (9.4%) 326 (9.4%) 1 (5.0%) 0.429
Hypertension 2840 (81.3%) 2823 (81.3%) 17 (85.0%) 0.470
Dyslipidemia 2349 (67.2%) 2337 (67.3%) 12 (60.0%) 0.318
Diabetes mellitus 1298 (46.3%) 1288 (46.2%) 10 (50.0%) 0.147
Hemodialysis 198 (5.7%) 197 (5.7%) 1 (5.0%) 0.685
Current smoker 745 (21.3%) 741 (21.4%) 4 (20.0%) 0.571
ACS 1275 (36.5%) 1262 (36.3%) 13 (65.0%) 0.009
Killip 3 2 210 (8.4%) 210 (8.4%) 0 (0%) 0.188
ACS, acute coronary syndrome; BMI, body mass index; CABG, coronary artery bypass graft; HbA1c, glycated hemoglobin A1c; MI, myocardial infarction; PAD, peripheral
artery disease; ST, stent thrombosis.
Table 1B
Comparison of angiographic characteristics between non-stent thrombosis and stent thrombosis.
All (n = 3493) Non-ST (n = 3473) ST (n = 20) p
Emergent PCI 574 (17.0%) 584 (16.8%) 10 (50.0%) <0.001
IVUS 2472 (70.8%) 2466 (71.0%) 6 (30.0%) <0.001
Distal protection 87 (2.5%) 87 (2.5%) 0 (0%) 0.603
Thrombus aspiration 324 (9.3%) 320 (9.2%) 4 (20.0%) 0.108
Disease vessel 3 2 1737 (50.5%) 1730 (50.5%) 7 (35.0%) 0.227
Left main lesion 227 (6.5%) 225 (6.5%) 2 (10.0%) 0.377
Lesion morphology B2 or C 2059 (60.0%) 2045 (59.9%) 14 (70.0%) 0.094
Mean stent diameter (mm) 3.2  0.5 2.9  0.8 2.5  0.7 0.033
Mean stent length (mm) 29.2  5.9 20.6  6.7 23.8  4.5 0.012
Post dilatation 2386 (68.3%) 2377 (68.4%) 10 (50.0%) 0.067
Rotational atherectomy 234 (6.7%) 232 (6.7%) 2 (10.0%) 0.392
IABP 102 (2.9%) 101 (2.9%) 1 (5.0%) 0.448
Cardiac ECMO 4 (0.1%) 4 (0.1%) 0 (0%) 0.977
Pre-stenosis 3 99% 1174 (33.7%) 1161 (33.5%) 13 (65.0%) 0.004
Post stenosis > 50% 349 (9.5%) 336 (9.5%) 3 (15.0%) 0.296
Procedural complications
Slow ﬂow or no reﬂow 142 (4.1%) 142 (4.1%) 0 (0%) 0.433
Acute occlusion 18 (0.5%) 16 (0.5%) 2 (10.0%) 0.005
Emergent CABG 5 (0.1%) 5 (0.1%) 0 (0%) 0.972
Stroke 12 (0.3%) 12 (0.3%) 0 (0%) 0.933
Bleeding 26 (0.7%) 26 (0.7%) 0 (0%) 0.927
CABG, coronary artery bypass graft; ECMO, extracorporeal membrane oxygenation; IABP, intra aortic balloon pumping; IVUS, intravascular ultrasonography; PCI,
percutaneous coronary intervention; ST, stent thrombosis.
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We also compared the rate of prescription drug use between the
ST and non-ST groups in EST, LST, and VLST, respectively (Table 2).
In 3493 patients who underwent DES implantation, 1790 patients
(51.2%) received a calcium channel blocker (CCB). Patients who
were relatively stable following DES implantation, without
congestive heart failure and with hypertension, tended to be
administered CCB after DES implantation. However, there was no
difference in patients’ background and lesion characteristics
between with and without CCB. Patients who were relatively
stable following DES implantation, without congestive heart
failure, ACS, and no classical risk factors, tended to be administered
CCB after DES implantation (Table 3A), while patients who were
relatively severe conditions, with multi-vessel disease and left
main trunk stenosis, had a tendency to avoid CCB (Table 3B). There
were 1459 (81.7%) patients who received a dihydropyridine agent,
314 (17.5%) who received a non-dihydropyridine agent, and 17
(0.8%) who received an unknown type of CCB. Nifedipine (all agentswere long-acting type) was the most commonly used agent
(571 patients, 31.9%). The rates of use of other prescription drugs
were similar between the two groups. The frequency of CCB use
was signiﬁcantly lower in the ST than the non-ST group (25.0%
versus 51.4%, respectively, p = 0.016). This tendency was promi-
nent in patients with both EST (12.5% versus 51.3%, p = 0.030) and
LST (12.5% versus 51.3%, p = 0.030). There was no signiﬁcant
difference in the use of aspirin and thienopyridine derivative
between ST and non-ST.
Clinical outcomes
We analyzed clinical outcomes according to CCB use (Table 3C).
The occurrence of all ST was lower in patients with than without
CCB use (0.3% versus 0.9%, p = 0.016). This tendency was observed
in cases of EST and LST, but not VLST. Moreover, there was less CV
death in patients who received a CCB (0.6% versus 1.4%, p = 0.020).
There were no signiﬁcant differences in all-cause death, non-CV
death, non-fatal MI, non-fatal stroke or bleeding due to any cause.
Table 3A
Comparison of clinical characteristics between CCB and non-CCB.
CCB () (n = 1703) CCB (+) (n = 1790) p
Male 1231 (72.3%) 1261 (70.5%) 0.127
Age (years) 69.5  10.8 70.2  9.7 0.039
BMI (kg/m2) 23.7  3.7 24.4  3.4 <0.001
HbA1c (%) 6.2  1.4 6.2  1.2 0.178
Prior MI 453 (26.6%) 407 (22.7%) 0.005
Prior CABG 111 (6.5%) 107 (6.0%) 0.278
Prior stroke 239 (14.0%) 252 (14.1%) 0.505
Prior PAD 133 (7.8%) 194 (10.8%) 0.001
Hypertension 1226 (72.0%) 1614 (90.2%) <0.001
Dyslipidemia 1140 (66.9%) 1209 (67.5%) 0.366
Diabetes mellitus 599 (44.3%) 699 (48.2%) 0.02
Hemodialysis 70 (4.1%) 128 (7.2%) <0.001
Current smoker 387 (22.7%) 358 (20.0%) 0.027
ACS 704 (41.3%) 571 (31.9%) <0.001
Killip 3 2 123 (9.5%) 87 (7.2%) 0.023
ACS, acute coronary syndrome; BMI, body mass index; CABG, coronary artery
bypass graft; CCB, Ca-channel blocker; HbA1c, glycated hemoglobin A1c; MI,
myocardial infarction; PAD, peripheral artery disease; ST, stent thrombosis.
Table 3B
Comparison of angiographic characteristics between CCB and non-CCB.
CCB () (n = 1703) CCB (+) (n = 1790) p
Emergent PCI 413 (24.3%) 181 (10.1%) <0.001
IVUS 1183 (69.5%) 1289 (72.0%) 0.053
Distal protection 40 (2.3%) 47 (2.6%) 0.339
Disease vessel 3 2 891 (53.3%) 846 (47.8%) 0.001
Left main lesion 127 (7.5%) 100 (5.6%) 0.015
Lesion morphology B2 or C 980 (58.8%) 1079 (61.1%) 0.086
Mean stent diameter (mm) 3.0  0.9 2.9  0.7 0.536
Mean stent length (mm) 21.0  6.7 20.2  6.6 0.001
Post dilatation 1133 (66.5%) 1253 (70.0%) 0.015
Rotablator 99 (5.8%) 135 (7.5%) 0.024
IABP 76 (4.5%) 26 (1.5%) <0.001
Cardiac ECMO 3 (0.2%) 1 (0.1%) 0.294
Pre-stenosis 3 99% 673 (39.6%) 501 (28.1%) <0.001
Post stenosis > 50% 1525 (90.0%) 1619 (90.9%) 0.204
Procedural complications
Slow ﬂow or no reﬂow 87 (5.1%) 55 (3.1%) 0.001
Acute occlusion 7 (0.4%) 11 (0.6%) 0.274
Emergent CABG 3 (0.2%) 2 (0.1%) 0.477
Stroke 9 (0.5%) 3 (0.2%) 0.061
Bleeding 13 (0.7%) 13 (0.7%) 0.992
CABG, coronary artery bypass graft; CCB, Ca-channel blocker; ECMO,
extracorporeal membrane oxygenation; IABP, intra aortic balloon pumping;
IVUS, intravascular ultrasonography; PCI, percutaneous coronary intervention;
ST, stent thrombosis.
Fig. 2. Occurrence of stent thrombosis based on actual number of DES implanted.
Total 5371 DESs were implanted. SES (26.4%), PES (27.6%), and EES (25.8%) were the
major stent types used in this study. The occurrence of ST was 0.49% in SES, 0.40% in
PES, 0.35% in ZES, and 0.25% in EES. EES showed lower rate of ST occurrence
compared with any other stents, especially ﬁrst-generation stent (SES and PES).
DES, drug-eluting stent; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent;
ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent.
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We examined predictors of ST using both univariate and
multivariate Cox regression models. In univariate analysis, ACS,
severe pre-stenosis (>99%), longer stent length (>20 mm), and the
non-use of CCB were predictors of all ST (EST + LST + VLST). In
multivariate analysis, only longer stent length was an independent
predictor of all ST (OR, 7.142; 95% CI, 1.604–31.801; p = 0.01)
(Table 4A). Given that there may be a relation between non-use of
CCB and ST within 1 year, we performed multivariate analysis for
ST within 1 year (Table 4B) or more than 1 year (Table 4C). For ST
within 1 year, ACS, longer stent length, and lack of CCB use were
predictors in univariate analysis. In multivariate analysis, ACS (OR,
3.715; 95% CI, 1.069–12.909; p = 0.039), longer stent length
(OR, 5.239; 95% CI, 1.132–24.252; p = 0.034), and lack of CCB
use (OR, 0.209; 95% CI, 0.045–0.973; p = 0.046) were independent
predictors of ST within 1 year (Table 4B). For ST more than 1 year,
multivariate analysis showed there were no independent
predictors of ST (Table 4C).
Discussion
ST is a rare, but severe complication after coronary stenting.
Although especially, VLST has come to the front in the DES era, STTable 2
Comparison of prescription drug use among early, late, and very late stent thrombosis
All ST (n = 20) EST (n = 8) 
Non-ST ST p Non-EST EST 
Aspirin 3439 (99.0%) 19 (95.0%) 0.183 3451 (99.0%) 7 (87.5%) 
Thienopyridine 3380 (97.3%) 19 (95.0%) 0.421 3392 (97.3%) 7 (87.5%) 
Nitrate 680 (19.6%) 3 (15.0%) 0.431 683 (19.6%) 0 (0%) 
Statin 2524 (72.7%) 13 (65.0%) 0.294 2530 (72.6%) 7 (87.5%) 
Beta-blocker 1364 (39.3%) 8 (40.0%) 0.558 1367 (39.2%) 5 (62.5%) 
CCB 1785 (51.4%) 5 (25.0%) 0.016 1789 (51.3%) 1 (12.5%) 
ACEI/ARB 2393 (68.9%) 15 (75.0%) 0.376 2401 (68.9%) 7 (87.5%) 
Insulin 165 (4.8%) 1 (5.0%) 0.623 166 (4.8%) 0 (0%) 
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CCB
MI, myocardial infarction; ST, stent thrombosis; VLST, very late stent thrombosis.through 1 year (i.e. EST and LST) is also a problem needing to be
solved irrespective of DES or BMS [13]. We demonstrated that ACS,
longer stent length, and lack of CCB use were associated with an
increased risk of ST after DES implantation within 1 year in groups.
LST (n = 8) VLST (n = 4)
p Non-LST LST p Non-VLST VLST p
0.077 3450 (99.0%) 8 (100%) 0.923 3454 (99.0%) 4 (100%) 0.961
0.196 3391 (97.3%) 8 (100%) 0.804 3395 (97.3%) 4 (100%) 0.897
0.175 681 (19.5%) 2 (25.0%) 0.484 682 (19.5%) 1 (25.0%) 0.302
0.311 2533 (72.7%) 4 (50.0%) 0.149 2535 (72.7%) 2 (50.0%) 0.581
0.162 1370 (39.3%) 2 (25.0%) 0.330 1371 (39.3%) 1 (25.0%) 0.488
0.030 1789 (51.3%) 1 (12.5%) 0.030 1787 (51.2%) 3 (75.0%) 0.331
0.235 2402 (68.9%) 6 (75.0%) 0.525 2406 (69.0%) 2 (50.0%) 0.367
0.677 165 (4.7%) 1 (12.5%) 0.323 166 (4.8%) 0 (0%) 0.823
, calcium channel blocker; EST, early stent thrombosis; LST, late stent thrombosis;
Table 3C
Comparison of clinical outcomes according to calcium channel blocker use.
CCB () CCB (+) p
n = 1703 (43.7%) n = 1790 (55.1%)
All-cause death 41 (2.4%) 41 (2.3%) 0.453
Cardiovascular death 23 (1.4%) 11 (0.6%) 0.020
Non-cardiovascular death 18 (1.1%) 30 (1.7%) 0.076
Non-fatal MI 12 (0.7%) 11 (0.6%) 0.452
Non-fatal stroke 10 (0.6%) 14 (0.8%) 0.312
Any bleeding 9 (0.5%) 11 (0.6%) 0.456
All ST 15 (0.9%) 5 (0.3%) 0.016
EST 7 (0.4%) 1 (0.1%) 0.030
LST 7 (0.4%) 1 (0.1%) 0.030
VLST 1 (0.1%) 3 (0.2%) 0.331
CCB, calcium channel blocker; EST, early stent thrombosis; LST, late stent
thrombosis; MI, myocardial infarction; ST, stent thrombosis; VLST, very late
stent thrombosis.
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rence of ST is lower than in Western countries. Kimura et al.
assessed the incidence of ST in 10,778 patients who underwent SES
implantation in Japan, and they reported an incidence of 0.34% at
30 days, 0.54% at 1 year, and 0.77% at 2 years [3]. Daemen et al.
assessed the incidence of ST in 8146 patients who underwent SES
or PES implantation in the Netherlands. The incidence of ST was
1.2% at 30 days, 1.7% at 1 year, and 2.3% at 2 years [5]. If subjects
were limited to those with ACS who underwent PCI, this tendency
was more prominent [14]. Therefore, there are limited data to
predict ST occurrence in Japan.Table 4A
Multiple logistic regression analysis for all stent thrombosis.
All ST Univariate analysis 
OR 95% CI 
Age > 75 years 0.748 (0.287–1.951) 
Disease vessel > 1 0.623 (0.241–1.610) 
Acute coronary syndrome 3.254 (1.295–8.176) 
Dyslipidemia 0.729 (0.297–1.789) 
HbA1c > 6.5% 2.381 (0.863–6.571) 
Serum creatinine > 1.3 mg/dL 1.819 (0.658–5.026) 
Pre-stenosis 3 99% 3.684 (1.466–9.258) 
Smaller stent diameter (<3 mm) 2.495 (0.851–7.315) 
Longer stent length (>20 mm) 8.473 (1.922–37.345) 
Aspirin 0.188 (0.024–1.443) 
Beta blocker 1.031 (0.420–2.528) 
Calcium channel blocker 0.315 (0.114–0.869) 
CI, conﬁdence interval; HbA1c, glycated hemoglobin A1c; OR, odds ratio; ST, stent th
Table 4B
Multiple logistic regression analysis for stent thrombosis within 1 year.
ST within 1 year Univariate analysis 
OR 95% CI 
Age > 75 years 0.793 (0.275–2.289) 
Disease vessel > 1 0.587 (0.213–1.619) 
Acute coronary syndrome 5.259 (1.693–16.340) 
Dyslipidemia 0.811 (0.294–2.237) 
HbA1c > 6.5% 1.901 (0.658–5.496) 
Serum creatinine > 1.3 mg/dL 1.817 (0.584–5.656) 
Pre-stenosis 3 99% 2.542 (0.944–6.842) 
Smaller stent diameter (<3 mm) 2.179 (0.637–7.460) 
Longer stent length (>20 mm) 6.035 (1.320–27.589) 
Aspirin 0.148 (0.019–1.153) 
Beta blocker 1.203 (0.447–3.239) 
Calcium channel blocker 0.135 (0.031–0.595) 
CI, conﬁdence interval; HbA1c, glycated hemoglobin A1c; OR, odds ratio; ST, stent thIt is thought that the frequency of coronary spastic angina is
higher in Japan than Western countries. Pristipino et al. performed
a provocation test for coronary spasm in patients with recent MI,
and examined the differences between Japanese and Italian
patients [15]. They reported that Japanese patients exhibited a
3-fold greater incidence of spasm and more vasoconstriction of
non-spastic segments after intracoronary injection of acetylcho-
line compared with Caucasians. Because of a higher incidence of
spasm, Japanese patients with ischemic heart disease tend to
receive CCBs rather than beta-blockers (BBs). The use of CCBs was
higher than BBs in our subjects (51.4% versus 39.3%, respectively).
We previously compared the effects of BBs on cardiovascular
events with those of CCBs in Japanese post-MI patients [16]. That
study demonstrated that the incidences of heart failure and
coronary spasm were signiﬁcantly higher in the BBs group than in
the CCBs group, and there were no signiﬁcant differences in any
other CV events between both groups. Although we could not
determine whether patients in this study had coronary spasm,
there is a possibility that coronary spasm may be associated with
ST occurrence because several patients had chest pain at rest. We
do not recommend the use of CCBs in all patients following DES
implantation, and coronary spasm may be one of the etiologies of
ST, so CCB use may be considered in patients with a history of chest
pain at rest.
In multivariate regression analysis, the lack of CCB use was an
independent predictor of ST within 1 year. There is some concern
that ST could be caused by coronary spasm in patients not
receiving a CCB. In this study, ACS accounted for 65% of primary
illness in the ST group. For patients with ACS, it was sometimesMultivariate analysis
p OR 95% CI p
0.552 – – –
0.329 – – –
0.009 2.129 (0.761–5.953) 0.15
0.490 – – –
0.072 – – –
0.249 – – –
0.004 2.703 (0.940–7.774) 0.065
0.072 – – –
0.001 7.142 (1.604–31.801) 0.01
0.108 – – –
0.558 0.688 (0.245–1.930) 0.477
0.016 0.483 (0.164–1.424) 0.187
rombosis.
Multivariate analysis
p OR 95% CI p
0.669 – – –
0.304 – – –
0.002 3.715 (1.069–12.909) 0.039
0.686 – – –
0.235 – – –
0.302 – – –
0.053 1.335 (0.409–4.363) 0.632
0.215 – – –
0.008 5.239 (1.132–24.252) 0.034
0.068 – – –
0.714 0.776 (0.242–2.489) 0.67
0.002 0.209 (0.045–0.973) 0.046
rombosis.
Table 4C
Multiple logistic regression analysis for stent thrombosis more than 1 year.
ST more than 1 year Univariate analysis Multivariate analysis
OR 95% CI p OR 95% CI p
Age > 75 years 0.582 (0.060–5.602) 0.640 – – –
Disease vessel > 1 0.981 (0.061–15.696) 0.989 – – –
Acute coronary syndrome 0.58 (0.060–5.577) 0.637 0.49 (0.049–4.858) 0.542
Dyslipidemia 0.487 (0.068–3.459) 0.472 – – –
HbA1c > 6.5% – – 0.988 – – –
Serum creatinine > 1.3 mg/dL 1.813 (0.188–17.461) 0.607 – – –
Pre-stenosis 3 99% – – 0.985 – – –
Smaller stent diameter (<3 mm) 3.732 (0.388–35.913) 0.254 – – –
Longer stent length (>20 mm) – – 0.987 – – –
Aspirin – – 0.998 – – –
Beta blocker 0.515 (0.054–4.956) 0.566 0.434 (0.044–4.304) 0.476
Calcium channel blocker 2.857 (0.063–3.200) 0.363 2.932 (0.290–29.649) 0.362
CI, conﬁdence interval; HbA1c, glycated hemoglobin A1c; OR, odds ratio; ST, stent thrombosis.
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endothelium. The underlying plaque morphology may affect the
rate of healing when stent struts penetrate deeply into a necrotic
core and are not in contact with cellular areas [17]. Inﬂammatory
cells, such as macrophages and T-cell lymphocytes, may accumu-
late more on these foundations. Coronary spasm on such
foundations might easily lead to plaque rupture to ST. Moreover,
there is no direct evidence or report that inhibition of coronary
spasm by use of CCBs might reduce the risk of ST, although DAPT is
reported to lead to a decreased risk of ST in the early phase after
DES implantation. However, this study might suggest the efﬁcacy
of CCBs for suppression of coronary spasm. It is thought that
inﬂammation may have an important role in the pathogenesis of
coronary spasm [18,19]. Given that there was a decreased risk of ST
with CCB use, although the relation between coronary spasm and
ST is unclear, there is a possibility that coronary spasm may be
associated with the pathogenesis of ST as well as pathophysiology
of ischemic heart diseases. Although it has been said that BBs have
adverse effects for coronary spasm, the use of BBs was not
associated with increased risk of ST in this study. BBs with beta-1
selectivity, which have little effect on vasodilation, were pre-
scribed for many BB users (516 patients; 37.9%). Therefore, it was
thought that BB use was not associated with ST occurrence. Nitrate
agents have effects on vasodilatation according to nitric oxide
production and tolerance should occur in long-term use. In this
study, although the frequency of nitrate agent use tended to be
lower in the EST group than in the non-EST group, there were no
differences between LST and non-LST groups or VLST and non-VLST
groups.
In this study, ACS was also an independent predictor of ST. It is
thought that patients who undergo PCI during ACS are exposed to a
higher risk of ST than those who undergo elective stenting.
Previous studies reported that the incidence of ST in ACS patients
was higher (2.2–4.4%) than in patients who undergo elective
stenting [4,20,21]. In this study, the incidence of ST was 1.02% in
ACS patients but only 0.32% in non-ACS patients, and these results
are consistent with previous data.
Longer stent length was also an independent predictor of ST in
the present study. Caputo et al. reported that a longer DES length
was associated with increased adverse events (major adverse
cardiac events including MI and target lesion revascularization).
Although DES length was not an independent predictor of adverse
events in that study, there was a tendency for an increased risk
(p = 0.1) [22]. Stent length could well be associated with any CV
event, including ST.
Although diabetes mellitus (DM) has emerged as a strong risk
factor of cardiovascular events, DM was not an independent
predictor for ST incidence in this study. Billinger et al. analyzedclinical outcomes according to diabetic status in patients who
underwent DES implantation. They reported that DM contributed
increasing risk for mortality, but DM was not associated with an
increased risk of ST and target-lesion revascularization [23]. These
results were similar to those of the present study.
We examined the rate of any prescription drug use according to
the presence of ST. ST patients had a lower frequency of CCB use
compared with non-ST patients. On the other hand, patients in
both groups received DAPT. DAPT, especially aspirin and thieno-
pyridine, are currently used as standard medical therapy after PCI.
Previous studies reported that thienopyridine, clopidogrel, and
CCBs are all metabolized by hepatic cytochrome 450 3A4, so it has
been controversial whether there is interaction between these
agents [24,25]. In this study, patients who received a CCB had a
lower occurrence of ST and CV death than patients without a CCB;
however, the majority of patients were receiving thienopyridines.
It is possible that the vasodilatory effects of CCBs were more
important than their interaction with other drugs.
Limitations
This study was implemented as an observational study rather
than an interventional study, and it is therefore not clear if patient
management during and after PCI could have inﬂuenced the
incidence of ST. Buonamici et al. reported that non-responsiveness
to clopidogrel was a strong independent predictor of ST in patients
who received DESs [26]. Thus, it might be useful to investigate the
role of platelet reactivity in the occurrence of ST in this population.
Although we suggested the possibility of decreased risk of ST by use
of CCBs, we have no data on comparison of actual blood pressure
levels between patients with and without taking CCBs. We could not
examine the impact of lowering blood pressure on ST occurrence.
In this study, a total of 5371 drug-eluting stents were implanted.
SES (26.4%), PES (27.6%), and EES (25.8%) were the major stent types
implanted. The occurrence of ST was similar among these three stent
types (about 0.3% with each stent type). Palmerini et al. reported that
the cobalt–chromium EES had a lower rate of ST than any other stent
(BMS, PES, ZES, or SES) in a meta-analysis of multiple, randomized,
controlled trials [7]. Variation in stent type could possibly inﬂuence
ST occurrence. The small sample size and low incidence of ST in this
study made it impossible to determine if stent type was a predictor
of ST occurrence.
Conclusions
These results suggest that CCB use may be associated with a
decreased risk of ST after DES implantation within 1 year in
Japanese patients.
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